Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-21-5p AKT2 1.75 0 -0.01 0.9227 miRNAWalker2 validate -0.15 0.00352 NA
2 hsa-miR-29b-3p AKT2 -0.23 0.36746 -0.01 0.9227 MirTarget -0.14 0.00022 26512921; 26564501; 24076586 MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3;The expression of miR-29b was significantly upregualted by cisplatin treatmentwhile its target gene AKT2 was downregulated;Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis
3 hsa-miR-106b-5p AKT3 1.71 0 -0.75 0.06936 miRNATAP -0.37 7.0E-5 NA
4 hsa-miR-107 AKT3 0.9 5.0E-5 -0.75 0.06936 PITA; miRanda -0.6 0 NA
5 hsa-miR-15b-5p AKT3 1.62 0 -0.75 0.06936 miRNATAP -0.36 0.00041 NA
6 hsa-miR-16-5p AKT3 1.01 1.0E-5 -0.75 0.06936 miRNAWalker2 validate; miRTarBase; miRNATAP -0.47 0.00031 NA
7 hsa-miR-17-3p AKT3 1.31 0 -0.75 0.06936 miRNATAP -0.52 0 NA
8 hsa-miR-17-5p AKT3 1.66 0 -0.75 0.06936 TargetScan; miRNATAP -0.28 0.0027 NA
9 hsa-miR-29a-3p AKT3 -0.11 0.61501 -0.75 0.06936 miRNATAP -0.41 0.00212 NA
10 hsa-miR-29b-3p AKT3 -0.23 0.36746 -0.75 0.06936 miRNATAP -0.34 0.00361 26512921 MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3
11 hsa-miR-32-3p AKT3 0.58 0.11837 -0.75 0.06936 mirMAP -0.32 0.00023 NA
12 hsa-miR-320b AKT3 1.11 0.0005 -0.75 0.06936 PITA; miRanda; miRNATAP -0.26 0.0039 NA
13 hsa-miR-335-3p AKT3 2.52 0 -0.75 0.06936 mirMAP -0.22 0.00074 NA
14 hsa-miR-33a-3p AKT3 0.35 0.32171 -0.75 0.06936 mirMAP -0.38 2.0E-5 NA
15 hsa-miR-362-3p AKT3 -0.03 0.91378 -0.75 0.06936 miRanda -0.38 4.0E-5 NA
16 hsa-miR-362-5p AKT3 -0.35 0.35491 -0.75 0.06936 PITA; TargetScan; miRNATAP -0.23 0.00253 NA
17 hsa-miR-501-3p AKT3 0.73 0.02704 -0.75 0.06936 miRNATAP -0.39 1.0E-5 NA
18 hsa-miR-502-3p AKT3 -0.16 0.55747 -0.75 0.06936 miRNATAP -0.5 0 NA
19 hsa-miR-505-3p AKT3 0.83 0.00112 -0.75 0.06936 mirMAP -0.35 0.00235 22051041 We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR
20 hsa-miR-548v AKT3 -0.16 0.70867 -0.75 0.06936 miRNATAP -0.27 0.00031 NA
21 hsa-miR-577 AKT3 0.91 0.22561 -0.75 0.06936 mirMAP -0.23 0 NA
22 hsa-miR-616-5p AKT3 0.83 0.03478 -0.75 0.06936 mirMAP -0.27 0.00041 NA
23 hsa-miR-193b-3p CASP9 0.28 0.45126 -0.31 0.11004 miRNAWalker2 validate -0.17 0 NA
24 hsa-miR-577 HSPB1 0.91 0.22561 0.99 0.06197 PITA -0.31 0 NA
25 hsa-miR-149-5p KDR 0.71 0.29685 -0.7 0.04936 miRNATAP -0.22 0 NA
26 hsa-miR-23a-3p KDR 1.11 0 -0.7 0.04936 mirMAP -0.55 1.0E-5 NA
27 hsa-let-7a-3p KRAS 0.5 0.04111 0.04 0.88822 mirMAP; miRNATAP -0.27 0.00252 24727325; 20603437; 24890702; 23324806; 21994416; 23167843; 27620744; 20177422; 25183481; 22584434; 18922928 Association study of the let 7 miRNA complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer NCCTG N0147 Clinical Trial; A let-7 microRNA-complementary site LCS6 polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression;A let 7 microRNA binding site polymorphism in 3' untranslated region of KRAS gene predicts response in wild type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy; A polymorphism in a let-7 microRNA complementary site lcs6 in the KRAS 3' untranslated region UTR is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival OS in oral cancers; the presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy IMCL-0144; KRAS let-7 lcs6 polymorphism was found to be related to object response rate ORR in mCRC patients whose tumors had KRASwt;Let 7 microRNA binding site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta analysis; There is a small but growing body of literature regarding the predictive utility of a Let-7 microRNA-binding-site polymorphism in the 3'-untranslated region UTR of KRAS KRAS-LCS6 for colorectal cancer outcome although the results are conflicting; A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism LCS6; rs61764370 and colorectal cancer outcome;The LCS6 polymorphism in the binding site of let 7 microRNA to the KRAS 3' untranslated region: its role in the efficacy of anti EGFR based therapy in metastatic colorectal cancer patients; The lethal-7 let-7 family of microRNAs regulates KRAS activity; We studied the association of the KRAS let-7 LCS6 polymorphism with the response in 100 refractory mCRC patients treated with anti-EGFR antibodies; The KRAS let-7 LCS6 polymorphism was genotyped using the BioMark system in blood and tumor DNA samples; The KRAS let-7 LCS6 G-allele showed a statistically significant association with nonresponse to anti-EGFR-based treatment: 31.9% of patients with the T/T genotype presented a complete or a partial response versus no patients with T/G or G/G genotypes P=0.004;A let 7 microRNA SNP in the KRAS 3'UTR is prognostic in early stage colorectal cancer; Recently a SNP in a lethal-7 let-7 miRNA complementary site LCS6 in the KRAS 3'untranslated region was suggested to affect survival in metastatic CRC;Let 7 miRNA binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5 fluorouracil and oxaliplatin +/ cetuximab; Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site LCS6 within the 3'untranslated region 3'UTR of KRAS rs61764370 and clinical outcome in metastatic colorectal cancer mCRC patients receiving cetuximab;A let 7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population; The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3' untranslated region rs61764370 T/G of KRAS leads to its higher expression;Genetic modulation of the Let 7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab irinotecan; There is increasing evidence that the Let-7 microRNA miRNA exerts an effect as a tumor suppressor by targeting the KRAS mRNA; The Let-7 complementary site LCS6 T>G variant in the KRAS 3'-untranslated region weakens Let-7 binding;A let 7 microRNA binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy;High let 7a microRNA levels in KRAS mutated colorectal carcinomas may rescue anti EGFR therapy effects in patients with chemotherapy refractory metastatic disease; Preclinical and experimental data in vivo indicate that Lethal-7 Let-7 microRNA downregulates KRAS with antitumor effects in the presence of activating KRAS mutations; In 59 patients harboring KRAS mutations Let-7a levels were analyzed for association with overall survival OS and progression-free survival PFS times; An exploratory subgroup analysis was performed using the rs61764370 LCS6 T>G polymorphism that experimentally impairs Let-7 binding to KRAS mRNA; In patients with KRAS mutations Let-7a analysis may serve to identify subgroups of patients who may still benefit from EGFR inhibition and this may open up new perspectives for alternative treatment strategies;A SNP in a let 7 microRNA complementary site in the KRAS 3' untranslated region increases non small cell lung cancer risk; The purpose of this study was to identify single nucleotide polymorphisms SNP that could modify let-7 binding and to assess the effect of such SNPs on target gene regulation and risk for non-small cell lung cancer NSCLC let-7 complementary sites LCS were sequenced in the KRAS 3' untranslated region from 74 NSCLC cases to identify mutations and SNPs that correlated with NSCLC; The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers and represents a new paradigm for let-7 miRNAs in lung cancer susceptibility
28 hsa-miR-143-3p KRAS -0.66 0.04832 0.04 0.88822 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.18 0.00744 22804917; 27725862; 19137007; 26581910; 23173124; 26824186; 21197560 In KRAS mutated tumours increased miR-200b and decreased miR-143 expression were associated with a good PFS;The expression of miR-143 is often down-regulated and it might play an important role by targeting KRAS in colorectal cancer CRC; Dual-luciferase reporter assays were performed to validate whether KRAS was regulated by miR-143; Dual-luciferase assays indicated that KRAS was a direct target of miR-143 as subsequently demonstrated by qPCR and western blot analysis showing that infection of SW480 cells with Ad-ZD55-miR-143 resulted in the down-regulation of KRAS at both mRNA and protein levels;Role of miR 143 targeting KRAS in colorectal tumorigenesis; In particular among a panel of presumed targets generated by in silico analysis that may interact with these aberrantly expressed miRNAs KRAS oncogene has been further experimentally validated as the target of miR-143; First an inverse correlation between KRAS protein and miR-143 in vivo was found; Second KRAS expression in Lovo cells was significantly abolished by treatment with miR-143 mimic whereas miR-143 inhibitor increased KRAS protein level; Third luciferase reporter assay confirmed that miR-143 directly recognize the 3'-untranslated region of KRAS transcripts; Finally inhibition of KRAS expression by miR-143 inhibits constitutive phosphorylation of ERK1/2; Taken together the present study provides the first evidences that miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation;MicroRNA 143 replenishment re sensitizes colorectal cancer cells harboring mutant but not wild type KRAS to paclitaxel treatment; Our results showed that miR-143 but not let-7b increased sensitization of KRAS mutant tumor cells to paclitaxel; Furthermore transfection of miR-143 but not let-7b mimic negatively regulated the expression of mutant but not wild-type KRAS; Combination of miR-143 mimic and paclitaxel induced the onset of apoptosis and reverted in vitro metastatic properties migration and invasion in KRAS mutant tumor cells; MiR-143 thus can be used as a chemosensitizer for the treatment of KRAS mutant tumors and warrants further investigations in in vitro and pre-clinical in vivo models;In turn the level of miR-143 in CRC cells decreasing the amount of MACC1 metastasis-associated in colon cancer-1 and oncogenic KRAS protein may be utilized as a prognostic marker;Stable miR-143 or miR-145 overexpression increased cell sensitivity to cetuximab resulting in a significant increase of cetuximab-mediated ADCC independently of KRAS status;miR 143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS; The expression level of miR-143 and its target gene KRAS were measured by realtime PCR and western blotting respectively; Our results revealed an inverse correlation of expression between miR-143 and KRAS protein in prostate cancer samples Pearson's correlation scatter plots: R = -0.707 P < 0.05; These findings suggest that miR-143 plays an important role in prostate cancer proliferation migration and chemosensitivity by suppressing KRAS and subsequent inactivation of MAPK pathway which provides a potential development of a new approach for the treatment of prostate cancer
29 hsa-miR-193b-3p KRAS 0.28 0.45126 0.04 0.88822 miRNAWalker2 validate; MirTarget; miRNATAP -0.2 0.00063 25905463 Deregulation of the MiR 193b KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer; Mechanistically KRAS was verified as a direct effector of miR-193b through which the AKT and ERK pathways were modulated and cell growth of PDAC cells was suppressed; Taken together our findings indicate that miR-193b-mediated deregulation of the KRAS axis is involved in pancreatic carcinogenesis and suggest that miR-193b could be a potentially effective target for PDAC therapy
30 hsa-miR-224-3p KRAS 1.52 0.0065 0.04 0.88822 mirMAP -0.11 0.00837 25919696 MicroRNA 224 is associated with colorectal cancer progression and response to 5 fluorouracil based chemotherapy by KRAS dependent and independent mechanisms; MicroRNA-224 was differentially expressed in dysplastic colorectal disease and in isogeneic KRAS WT and mutant HCT116 cells; 5-FU chemosensitivity was significantly increased in miR-224 knockdown cells and in NIH3T3 cells expressing KRAS and BRAF mutant proteins
31 hsa-miR-27b-3p KRAS 0.08 0.72527 0.04 0.88822 miRNATAP -0.31 0.00105 NA
32 hsa-miR-101-3p MAP2K1 -0.45 0.02834 0.35 0.02947 miRNAWalker2 validate -0.21 0.00016 NA
33 hsa-miR-140-3p MAP2K1 -0.3 0.12754 0.35 0.02947 PITA -0.25 2.0E-5 NA
34 hsa-miR-30c-5p MAP2K1 -0.98 5.0E-5 0.35 0.02947 miRNAWalker2 validate -0.19 5.0E-5 NA
35 hsa-miR-497-5p MAP2K1 -0.8 0.0036 0.35 0.02947 miRNAWalker2 validate -0.23 0 NA
36 hsa-miR-126-5p MAPK1 0.42 0.07532 -0.5 0.00057 mirMAP -0.12 0.00476 NA
37 hsa-miR-140-3p MAPK1 -0.3 0.12754 -0.5 0.00057 PITA; miRNATAP -0.15 0.00713 NA
38 hsa-miR-140-5p MAPK1 0.21 0.303 -0.5 0.00057 miRanda -0.17 0.00108 NA
39 hsa-miR-142-5p MAPK1 1.56 1.0E-5 -0.5 0.00057 mirMAP -0.12 2.0E-5 NA
40 hsa-miR-16-5p MAPK1 1.01 1.0E-5 -0.5 0.00057 mirMAP -0.13 0.00527 NA
41 hsa-miR-17-3p MAPK1 1.31 0 -0.5 0.00057 mirMAP -0.11 0.00661 NA
42 hsa-miR-32-5p MAPK1 0.42 0.10646 -0.5 0.00057 mirMAP -0.13 0.00101 NA
43 hsa-miR-320a MAPK1 0.59 0.0119 -0.5 0.00057 miRNAWalker2 validate; PITA; miRanda; miRNATAP -0.12 0.00441 NA
44 hsa-miR-320b MAPK1 1.11 0.0005 -0.5 0.00057 PITA; miRanda; miRNATAP -0.12 0.00017 NA
45 hsa-miR-3614-3p MAPK1 0.82 0.01436 -0.5 0.00057 mirMAP -0.14 0 NA
46 hsa-miR-361-3p MAPK11 -0.13 0.56605 -0.07 0.83024 mirMAP -0.41 0.00017 NA
47 hsa-miR-103a-3p NFAT5 0.84 0 -0.04 0.82158 MirTarget -0.26 0.0018 NA
48 hsa-miR-106b-5p NFAT5 1.71 0 -0.04 0.82158 MirTarget; miRNATAP -0.16 0.0002 NA
49 hsa-miR-107 NFAT5 0.9 5.0E-5 -0.04 0.82158 MirTarget -0.25 4.0E-5 NA
50 hsa-miR-148b-3p NFAT5 0.3 0.17466 -0.04 0.82158 miRNATAP -0.26 4.0E-5 NA
51 hsa-miR-15b-3p NFAT5 1.76 0 -0.04 0.82158 mirMAP -0.15 0.00028 NA
52 hsa-miR-15b-5p NFAT5 1.62 0 -0.04 0.82158 MirTarget -0.16 0.00111 NA
53 hsa-miR-16-5p NFAT5 1.01 1.0E-5 -0.04 0.82158 MirTarget -0.19 0.00261 NA
54 hsa-miR-17-3p NFAT5 1.31 0 -0.04 0.82158 mirMAP -0.19 0.00021 NA
55 hsa-miR-212-3p NFAT5 0.96 0.00133 -0.04 0.82158 miRNATAP -0.13 0.00454 NA
56 hsa-miR-24-3p NFAT5 1.09 0 -0.04 0.82158 miRNAWalker2 validate; miRNATAP -0.18 0.00301 NA
57 hsa-miR-26b-3p NFAT5 -0.01 0.96577 -0.04 0.82158 MirTarget; miRNATAP -0.16 0.0057 NA
58 hsa-miR-32-5p NFAT5 0.42 0.10646 -0.04 0.82158 miRNATAP -0.18 0.00113 NA
59 hsa-miR-320b NFAT5 1.11 0.0005 -0.04 0.82158 mirMAP -0.15 0.00047 NA
60 hsa-miR-330-3p NFAT5 0.8 0.00747 -0.04 0.82158 mirMAP -0.14 0.00306 NA
61 hsa-miR-33a-3p NFAT5 0.35 0.32171 -0.04 0.82158 mirMAP -0.12 0.00278 NA
62 hsa-miR-33a-5p NFAT5 0.41 0.32143 -0.04 0.82158 MirTarget -0.11 0.00088 NA
63 hsa-miR-340-5p NFAT5 -0.16 0.52991 -0.04 0.82158 MirTarget -0.14 0.00802 NA
64 hsa-miR-424-3p NFAT5 0.86 0.02346 -0.04 0.82158 miRNATAP -0.14 0.00037 NA
65 hsa-miR-652-3p NFAT5 1.03 0.00034 -0.04 0.82158 miRNAWalker2 validate -0.14 0.00292 NA
66 hsa-miR-421 NFATC1 1.81 0 -0.65 0.05297 miRanda -0.22 0.0008 NA
67 hsa-miR-127-3p NFATC2 0.21 0.46101 -1.6 0.00281 miRanda -0.44 0.00108 NA
68 hsa-miR-16-2-3p NFATC2 1.8 0 -1.6 0.00281 mirMAP -0.41 0.00072 NA
69 hsa-miR-182-5p NFATC2 0.89 0.03106 -1.6 0.00281 mirMAP -0.57 0 NA
70 hsa-miR-185-5p NFATC2 1.14 0 -1.6 0.00281 MirTarget -0.5 0.00829 NA
71 hsa-miR-193b-5p NFATC2 0.61 0.13924 -1.6 0.00281 MirTarget -0.68 0 NA
72 hsa-miR-214-3p NFATC2 1.01 0.00625 -1.6 0.00281 MirTarget; miRNATAP -0.35 0.00075 NA
73 hsa-miR-218-5p NFATC2 -0.99 0.01083 -1.6 0.00281 MirTarget -0.28 0.00423 NA
74 hsa-miR-2355-3p NFATC2 0.98 0.02293 -1.6 0.00281 mirMAP -0.45 0 NA
75 hsa-miR-2355-5p NFATC2 0.59 0.12059 -1.6 0.00281 MirTarget -0.53 0 NA
76 hsa-miR-24-3p NFATC2 1.09 0 -1.6 0.00281 MirTarget -1.45 0 NA
77 hsa-miR-27b-5p NFATC2 0.68 0.01497 -1.6 0.00281 mirMAP -0.42 0.00212 NA
78 hsa-miR-31-3p NFATC2 0.47 0.50687 -1.6 0.00281 MirTarget -0.2 0.00027 NA
79 hsa-miR-33a-3p NFATC2 0.35 0.32171 -1.6 0.00281 mirMAP -0.34 0.00353 NA
80 hsa-miR-452-5p NFATC2 2.09 0.00026 -1.6 0.00281 MirTarget; miRNATAP -0.58 0 NA
81 hsa-miR-493-5p NFATC2 0.96 0.00325 -1.6 0.00281 miRNATAP -0.39 0.00071 NA
82 hsa-miR-9-5p NFATC2 -0.2 0.76147 -1.6 0.00281 MirTarget -0.27 1.0E-5 NA
83 hsa-miR-30d-5p NFATC3 -0.55 0.01401 0.28 0.07069 MirTarget; miRNATAP -0.15 0.00355 NA
84 hsa-miR-362-3p NFATC3 -0.03 0.91378 0.28 0.07069 miRanda -0.13 0.00024 NA
85 hsa-miR-1254 NFATC4 0.94 0.06055 -0.98 0.00292 MirTarget -0.22 0.00012 NA
86 hsa-miR-130b-5p NFATC4 0.7 0.05101 -0.98 0.00292 mirMAP -0.2 0.00216 NA
87 hsa-miR-15b-3p NFATC4 1.76 0 -0.98 0.00292 mirMAP -0.4 0 NA
88 hsa-miR-185-3p NFATC4 1.34 3.0E-5 -0.98 0.00292 MirTarget -0.31 1.0E-5 NA
89 hsa-miR-29b-3p NFATC4 -0.23 0.36746 -0.98 0.00292 miRNATAP -0.27 0.00392 NA
90 hsa-miR-320a NFATC4 0.59 0.0119 -0.98 0.00292 miRanda; mirMAP -0.35 0.00047 NA
91 hsa-miR-320b NFATC4 1.11 0.0005 -0.98 0.00292 miRanda; mirMAP -0.33 0 NA
92 hsa-miR-320c NFATC4 0.46 0.24061 -0.98 0.00292 miRanda; mirMAP -0.23 0.00089 NA
93 hsa-miR-361-3p NFATC4 -0.13 0.56605 -0.98 0.00292 mirMAP -0.34 0.00205 NA
94 hsa-miR-429 NFATC4 1.4 0.009 -0.98 0.00292 miRNATAP -0.21 0 NA
95 hsa-miR-484 NFATC4 0.71 0.00234 -0.98 0.00292 MirTarget; miRNATAP -0.49 0 NA
96 hsa-miR-625-5p NFATC4 0.54 0.2038 -0.98 0.00292 mirMAP -0.16 0.00461 NA
97 hsa-miR-629-3p NFATC4 1.4 0.0001 -0.98 0.00292 mirMAP -0.28 1.0E-5 NA
98 hsa-miR-940 NFATC4 1.64 0.00069 -0.98 0.00292 miRNATAP -0.19 0.00086 NA
99 hsa-miR-542-3p NOS3 0.76 0.00211 -0.5 0.18108 miRanda -0.31 0.00446 NA
100 hsa-let-7c-5p NRAS -0.5 0.20685 0.61 0.01077 miRNAWalker2 validate; miRTarBase; MirTarget -0.12 0.00352 NA
101 hsa-miR-145-5p NRAS -1.75 2.0E-5 0.61 0.01077 miRNAWalker2 validate; MirTarget; miRNATAP -0.11 0.00563 26973415 miR-145 expression was significantly downregulated in colon cancer tissues with its expression in normal colonic tissues being 4-5-fold higher two sample t test P < 0.05 whereas N-ras expression showed the opposite trend
102 hsa-miR-26a-5p NRAS -0.38 0.04425 0.61 0.01077 mirMAP; miRNATAP -0.25 0.00537 26458859 MiR 26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2; Our results suggest that miR-26a can improve the sensitivity of GC cells to cisplatin-based chemotherapies through targeting NRAS and E2F2 and provide the first evidence of the potential utility of miR-26a as a sensitizer in chemotherapy for GC
103 hsa-miR-28-5p NRAS -0.24 0.16732 0.61 0.01077 MirTarget; PITA; miRanda; miRNATAP -0.31 0.00228 NA
104 hsa-miR-29c-3p NRAS -1.62 0 0.61 0.01077 miRNATAP -0.18 0.00053 NA
105 hsa-miR-126-5p PIK3CA 0.42 0.07532 0.18 0.37992 mirMAP -0.23 0.00023 NA
106 hsa-miR-146a-5p PIK3CA 1.82 2.0E-5 0.18 0.37992 mirMAP -0.13 8.0E-5 NA
107 hsa-miR-148a-5p PIK3CA -0.69 0.0793 0.18 0.37992 mirMAP -0.16 1.0E-5 NA
108 hsa-miR-148b-3p PIK3CA 0.3 0.17466 0.18 0.37992 miRNAWalker2 validate -0.27 6.0E-5 NA
109 hsa-miR-186-5p PIK3CA 0.15 0.43471 0.18 0.37992 mirMAP -0.28 0.00025 NA
110 hsa-miR-29b-1-5p PIK3CA 0.61 0.11636 0.18 0.37992 mirMAP -0.11 0.00515 NA
111 hsa-miR-320b PIK3CA 1.11 0.0005 0.18 0.37992 miRanda -0.13 0.00356 NA
112 hsa-miR-335-5p PIK3CA 1.6 6.0E-5 0.18 0.37992 miRNAWalker2 validate -0.14 7.0E-5 NA
113 hsa-miR-338-5p PIK3CA -1.2 0.01003 0.18 0.37992 mirMAP -0.13 3.0E-5 NA
114 hsa-miR-501-5p PIK3CA 0.27 0.45478 0.18 0.37992 mirMAP -0.18 0 NA
115 hsa-miR-7-1-3p PIK3CA 0.71 0.04123 0.18 0.37992 mirMAP -0.18 1.0E-5 NA
116 hsa-miR-130a-3p PIK3CB 0.15 0.63374 0.25 0.18038 miRNATAP -0.14 0.001 NA
117 hsa-miR-1468-5p PIK3CD -1.88 3.0E-5 0.39 0.25308 MirTarget -0.22 3.0E-5 NA
118 hsa-miR-30b-3p PIK3CD -0.27 0.40085 0.39 0.25308 MirTarget -0.43 0 NA
119 hsa-miR-30b-5p PIK3CD -0.43 0.05936 0.39 0.25308 MirTarget -0.48 1.0E-5 NA
120 hsa-miR-30d-5p PIK3CD -0.55 0.01401 0.39 0.25308 MirTarget; miRNATAP -0.67 0 NA
121 hsa-miR-616-5p PIK3CD 0.83 0.03478 0.39 0.25308 MirTarget -0.17 0.00628 NA
122 hsa-miR-7-5p PIK3CD 1.64 0.01244 0.39 0.25308 miRTarBase; MirTarget; miRNATAP -0.21 0 22234835 We first screened and identified a novel miR-7 target phosphoinositide 3-kinase catalytic subunit delta PIK3CD; A correlation between miR-7 and PIK3CD expression was also confirmed in clinical samples of HCC; By targeting PIK3CD mTOR and p70S6K miR-7 efficiently regulates the PI3K/Akt pathway
123 hsa-miR-103a-3p PIK3R1 0.84 0 -1.09 2.0E-5 MirTarget; miRNATAP -0.32 0.00394 NA
124 hsa-miR-106b-5p PIK3R1 1.71 0 -1.09 2.0E-5 MirTarget; miRNATAP -0.25 2.0E-5 NA
125 hsa-miR-107 PIK3R1 0.9 5.0E-5 -1.09 2.0E-5 MirTarget; PITA; miRanda; miRNATAP -0.24 0.00469 NA
126 hsa-miR-128-3p PIK3R1 0.98 6.0E-5 -1.09 2.0E-5 MirTarget -0.25 0.00086 25962360 miR 128 3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients; Mechanistically miR-128-3p was confirmed to regulate PIK3R1 p85α expression thereby suppressing phosphatidylinositol 3-kinase PI3K/AKT pathway activation using qRT-PCR and western blot analysis; Hence we conclude that miR-128-3p which is frequently downregulated in HCC inhibits HCC progression by regulating PIK3R1 and PI3K/AKT activation and is a prognostic marker for HCC patients
127 hsa-miR-144-3p PIK3R1 -0.13 0.79825 -1.09 2.0E-5 mirMAP -0.14 0.00013 NA
128 hsa-miR-15b-5p PIK3R1 1.62 0 -1.09 2.0E-5 MirTarget -0.32 0 NA
129 hsa-miR-16-2-3p PIK3R1 1.8 0 -1.09 2.0E-5 MirTarget -0.27 0 NA
130 hsa-miR-16-5p PIK3R1 1.01 1.0E-5 -1.09 2.0E-5 MirTarget -0.41 0 NA
131 hsa-miR-17-5p PIK3R1 1.66 0 -1.09 2.0E-5 MirTarget; TargetScan; miRNATAP -0.19 0.00107 NA
132 hsa-miR-182-5p PIK3R1 0.89 0.03106 -1.09 2.0E-5 miRNATAP -0.16 0.0004 NA
133 hsa-miR-185-5p PIK3R1 1.14 0 -1.09 2.0E-5 miRNATAP -0.42 0 NA
134 hsa-miR-188-5p PIK3R1 1.35 0.00038 -1.09 2.0E-5 MirTarget -0.16 0.00078 NA
135 hsa-miR-200b-3p PIK3R1 0.97 0.0595 -1.09 2.0E-5 mirMAP -0.1 0.0041 NA
136 hsa-miR-200c-3p PIK3R1 1.28 0.0037 -1.09 2.0E-5 mirMAP -0.14 0.00064 NA
137 hsa-miR-20a-5p PIK3R1 1.45 0 -1.09 2.0E-5 MirTarget; miRNATAP -0.18 0.00561 NA
138 hsa-miR-21-5p PIK3R1 1.75 0 -1.09 2.0E-5 miRNAWalker2 validate; MirTarget; miRNATAP -0.31 0.00155 26676464 PIK3R1 targeting by miR 21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT and predicts clinical outcome of breast cancer; Next we identified the PIK3R1 as a direct target of miR-21 and showed that it was negatively regulated by miR-21; Taken together we provide novel evidence that miR-21 knockdown suppresses cell growth migration and invasion partly by inhibiting PI3K/AKT activation via direct targeting PIK3R1 and reversing EMT in breast cancer
139 hsa-miR-212-3p PIK3R1 0.96 0.00133 -1.09 2.0E-5 MirTarget -0.23 0.00022 NA
140 hsa-miR-22-5p PIK3R1 0.8 0.0008 -1.09 2.0E-5 mirMAP -0.27 0.0005 NA
141 hsa-miR-221-3p PIK3R1 1.33 0 -1.09 2.0E-5 MirTarget -0.31 1.0E-5 NA
142 hsa-miR-222-3p PIK3R1 1.39 0 -1.09 2.0E-5 MirTarget -0.28 1.0E-5 NA
143 hsa-miR-3065-5p PIK3R1 -0.24 0.63312 -1.09 2.0E-5 MirTarget; mirMAP; miRNATAP -0.12 0.00106 NA
144 hsa-miR-32-3p PIK3R1 0.58 0.11837 -1.09 2.0E-5 mirMAP -0.17 0.00228 NA
145 hsa-miR-320b PIK3R1 1.11 0.0005 -1.09 2.0E-5 miRNATAP -0.16 0.00545 NA
146 hsa-miR-324-3p PIK3R1 1.05 0.00039 -1.09 2.0E-5 MirTarget; PITA; miRNATAP -0.18 0.00348 NA
147 hsa-miR-330-3p PIK3R1 0.8 0.00747 -1.09 2.0E-5 MirTarget; PITA; miRNATAP -0.26 2.0E-5 NA
148 hsa-miR-335-3p PIK3R1 2.52 0 -1.09 2.0E-5 mirMAP -0.15 0.0005 NA
149 hsa-miR-424-5p PIK3R1 1.09 0.00042 -1.09 2.0E-5 MirTarget -0.29 0 NA
150 hsa-miR-429 PIK3R1 1.4 0.009 -1.09 2.0E-5 mirMAP; miRNATAP -0.13 0.00023 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 INTRACELLULAR SIGNAL TRANSDUCTION 34 1572 8.618e-29 4.01e-25
2 IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 21 323 3.258e-26 7.579e-23
3 POSITIVE REGULATION OF RESPONSE TO STIMULUS 34 1929 7.869e-26 1.22e-22
4 FC RECEPTOR SIGNALING PATHWAY 18 206 1.076e-24 1.252e-21
5 FC EPSILON RECEPTOR SIGNALING PATHWAY 16 142 9.49e-24 8.831e-21
6 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 13 74 5.324e-22 4.129e-19
7 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY 20 498 1.026e-20 6.818e-18
8 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 30 1977 4.519e-20 2.628e-17
9 PLATELET ACTIVATION 14 142 5.938e-20 3.07e-17
10 REGULATION OF IMMUNE RESPONSE 22 858 1.018e-18 4.738e-16
11 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 20 689 5.974e-18 2.527e-15
12 REGULATION OF IMMUNE SYSTEM PROCESS 25 1403 9.312e-18 3.611e-15
13 CELL ACTIVATION 18 568 9.325e-17 3.337e-14
14 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 25 1656 4.673e-16 1.505e-13
15 POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS 20 867 5.034e-16 1.505e-13
16 ACTIVATION OF IMMUNE RESPONSE 16 427 5.176e-16 1.505e-13
17 PHOSPHORYLATION 22 1228 1.921e-15 5.257e-13
18 HEMOSTASIS 14 311 3.905e-15 1.009e-12
19 REGULATION OF BODY FLUID LEVELS 16 506 7.332e-15 1.796e-12
20 FC GAMMA RECEPTOR SIGNALING PATHWAY 10 95 9.998e-15 2.326e-12
21 POSITIVE REGULATION OF CELL COMMUNICATION 23 1532 1.472e-14 3.262e-12
22 REGULATION OF KINASE ACTIVITY 18 776 2.097e-14 4.436e-12
23 POSITIVE REGULATION OF IMMUNE RESPONSE 16 563 3.828e-14 7.745e-12
24 REGULATION OF PHOSPHORUS METABOLIC PROCESS 23 1618 4.731e-14 9.172e-12
25 ERBB SIGNALING PATHWAY 9 79 1.156e-13 2.151e-11
26 POSITIVE REGULATION OF LOCOMOTION 14 420 2.414e-13 4.32e-11
27 EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 8 55 3.831e-13 6.474e-11
28 CALCIUM MEDIATED SIGNALING 9 90 3.896e-13 6.474e-11
29 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 23 1805 4.803e-13 7.707e-11
30 PROTEIN PHOSPHORYLATION 18 944 5.917e-13 9.177e-11
31 REGULATION OF TRANSFERASE ACTIVITY 18 946 6.132e-13 9.204e-11
32 LOCOMOTION 19 1114 7.799e-13 1.134e-10
33 PHOSPHOLIPID METABOLIC PROCESS 13 364 8.385e-13 1.182e-10
34 WOUND HEALING 14 470 1.109e-12 1.474e-10
35 VASCULATURE DEVELOPMENT 14 469 1.077e-12 1.474e-10
36 INOSITOL PHOSPHATE MEDIATED SIGNALING 6 18 1.668e-12 2.157e-10
37 SECOND MESSENGER MEDIATED SIGNALING 10 160 2.028e-12 2.55e-10
38 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 17 876 2.395e-12 2.933e-10
39 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 18 1036 2.831e-12 3.293e-10
40 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 18 1036 2.831e-12 3.293e-10
41 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 7 40 3.156e-12 3.582e-10
42 PHOSPHOLIPID BIOSYNTHETIC PROCESS 11 235 3.331e-12 3.69e-10
43 IMMUNE SYSTEM PROCESS 23 1984 3.481e-12 3.767e-10
44 POSITIVE REGULATION OF MOLECULAR FUNCTION 22 1791 4.228e-12 4.471e-10
45 REGULATION OF TRANSPORT 22 1804 4.885e-12 5.051e-10
46 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 19 1275 8.379e-12 8.476e-10
47 LEUKOCYTE MIGRATION 11 259 9.558e-12 9.462e-10
48 REGULATION OF CELL DEATH 20 1472 1.021e-11 9.896e-10
49 PHAGOCYTOSIS 10 190 1.129e-11 1.072e-09
50 RESPONSE TO WOUNDING 14 563 1.25e-11 1.141e-09
51 REGULATION OF LIPID KINASE ACTIVITY 7 48 1.23e-11 1.141e-09
52 PHOSPHATIDYLINOSITOL METABOLIC PROCESS 10 193 1.319e-11 1.18e-09
53 ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY 10 195 1.461e-11 1.282e-09
54 CELL MOTILITY 16 835 1.535e-11 1.299e-09
55 LOCALIZATION OF CELL 16 835 1.535e-11 1.299e-09
56 POSITIVE REGULATION OF MAPK CASCADE 13 470 2.081e-11 1.729e-09
57 POSITIVE REGULATION OF GENE EXPRESSION 21 1733 2.157e-11 1.76e-09
58 POSITIVE REGULATION OF KINASE ACTIVITY 13 482 2.848e-11 2.285e-09
59 GLYCEROLIPID BIOSYNTHETIC PROCESS 10 211 3.19e-11 2.516e-09
60 GLYCEROPHOSPHOLIPID METABOLIC PROCESS 11 297 4.173e-11 3.237e-09
61 REGULATION OF CELLULAR COMPONENT MOVEMENT 15 771 6.325e-11 4.824e-09
62 REGULATION OF PHOSPHOLIPID METABOLIC PROCESS 7 61 7.132e-11 5.353e-09
63 CARDIOVASCULAR SYSTEM DEVELOPMENT 15 788 8.584e-11 6.241e-09
64 CIRCULATORY SYSTEM DEVELOPMENT 15 788 8.584e-11 6.241e-09
65 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 15 799 1.042e-10 7.459e-09
66 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 19 1492 1.272e-10 8.97e-09
67 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 17 1135 1.418e-10 9.85e-09
68 REGULATION OF CELL SUBSTRATE ADHESION 9 173 1.492e-10 1.021e-08
69 REGULATION OF PROTEIN MODIFICATION PROCESS 20 1710 1.535e-10 1.035e-08
70 POSITIVE REGULATION OF CATALYTIC ACTIVITY 19 1518 1.71e-10 1.137e-08
71 PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS 8 120 2.375e-10 1.556e-08
72 GLYCEROLIPID METABOLIC PROCESS 11 356 2.88e-10 1.861e-08
73 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 16 1021 3.022e-10 1.927e-08
74 NEGATIVE REGULATION OF CELL DEATH 15 872 3.516e-10 2.211e-08
75 IMMUNE EFFECTOR PROCESS 12 486 5.144e-10 3.191e-08
76 POSITIVE REGULATION OF VASCULATURE DEVELOPMENT 8 133 5.42e-10 3.318e-08
77 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 13 616 5.843e-10 3.531e-08
78 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 20 1848 6.113e-10 3.647e-08
79 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 8 138 7.279e-10 4.287e-08
80 ANGIOGENESIS 10 293 7.926e-10 4.61e-08
81 REGULATION OF RESPONSE TO STRESS 18 1468 8.743e-10 5.022e-08
82 T CELL RECEPTOR SIGNALING PATHWAY 8 146 1.141e-09 6.472e-08
83 REGULATION OF CELL MATRIX ADHESION 7 90 1.164e-09 6.525e-08
84 PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS 6 49 1.193e-09 6.61e-08
85 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 15 957 1.267e-09 6.934e-08
86 REGULATION OF MAPK CASCADE 13 660 1.351e-09 7.311e-08
87 POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 5 23 1.497e-09 8.005e-08
88 POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 6 51 1.532e-09 8.099e-08
89 LIPID BIOSYNTHETIC PROCESS 12 539 1.663e-09 8.694e-08
90 HOMEOSTATIC PROCESS 17 1337 1.764e-09 9.119e-08
91 REGULATION OF MAP KINASE ACTIVITY 10 319 1.802e-09 9.212e-08
92 LIPID PHOSPHORYLATION 7 99 2.284e-09 1.155e-07
93 POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION 5 25 2.355e-09 1.166e-07
94 PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 5 25 2.355e-09 1.166e-07
95 RESPONSE TO OXYGEN CONTAINING COMPOUND 17 1381 2.885e-09 1.413e-07
96 POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION 7 103 3.02e-09 1.464e-07
97 REGULATION OF EPITHELIAL CELL MIGRATION 8 166 3.157e-09 1.514e-07
98 ORGANOPHOSPHATE BIOSYNTHETIC PROCESS 11 450 3.376e-09 1.603e-07
99 RESPONSE TO EXTERNAL STIMULUS 19 1821 3.694e-09 1.736e-07
100 REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 6 59 3.781e-09 1.759e-07
101 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 11 470 5.305e-09 2.444e-07
102 REGULATION OF ENDOTHELIAL CELL MIGRATION 7 114 6.158e-09 2.809e-07
103 BLOOD VESSEL MORPHOGENESIS 10 364 6.383e-09 2.884e-07
104 REGULATION OF CYTOPLASMIC TRANSPORT 11 481 6.742e-09 3.016e-07
105 CELLULAR LIPID METABOLIC PROCESS 14 913 6.871e-09 3.045e-07
106 REGULATION OF INTRACELLULAR TRANSPORT 12 621 8.139e-09 3.573e-07
107 POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION 6 67 8.263e-09 3.593e-07
108 CELLULAR RESPONSE TO PEPTIDE 9 274 8.585e-09 3.699e-07
109 POSITIVE REGULATION OF TRANSPORT 14 936 9.426e-09 4.024e-07
110 ACTIVATION OF PROTEIN KINASE ACTIVITY 9 279 1.004e-08 4.249e-07
111 POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 12 1.092e-08 4.578e-07
112 REGULATION OF LIPID METABOLIC PROCESS 9 282 1.102e-08 4.578e-07
113 POSITIVE REGULATION OF MAP KINASE ACTIVITY 8 207 1.785e-08 7.349e-07
114 ERBB2 SIGNALING PATHWAY 5 39 2.494e-08 1.018e-06
115 RESPONSE TO NITROGEN COMPOUND 13 859 3.149e-08 1.274e-06
116 PEPTIDYL SERINE MODIFICATION 7 148 3.779e-08 1.516e-06
117 ORGANOPHOSPHATE METABOLIC PROCESS 13 885 4.471e-08 1.764e-06
118 REGULATION OF VASCULATURE DEVELOPMENT 8 233 4.474e-08 1.764e-06
119 RESPONSE TO ENDOGENOUS STIMULUS 16 1450 4.621e-08 1.807e-06
120 IMMUNE SYSTEM DEVELOPMENT 11 582 4.769e-08 1.849e-06
121 REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 17 5.208e-08 2.003e-06
122 REGULATION OF VESICLE MEDIATED TRANSPORT 10 462 6.072e-08 2.316e-06
123 REGULATION OF CELLULAR LOCALIZATION 15 1277 6.152e-08 2.327e-06
124 TAXIS 10 464 6.322e-08 2.372e-06
125 REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 6 95 6.867e-08 2.541e-06
126 REGULATION OF CELL DIFFERENTIATION 16 1492 6.881e-08 2.541e-06
127 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 9 360 8.984e-08 3.275e-06
128 REGULATION OF ADHERENS JUNCTION ORGANIZATION 5 50 9.01e-08 3.275e-06
129 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 8 258 9.817e-08 3.541e-06
130 REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION 5 51 9.972e-08 3.569e-06
131 TISSUE HOMEOSTASIS 7 171 1.019e-07 3.621e-06
132 REGULATION OF CELL ADHESION 11 629 1.047e-07 3.691e-06
133 CELLULAR RESPONSE TO GROWTH HORMONE STIMULUS 4 20 1.055e-07 3.691e-06
134 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 9 370 1.134e-07 3.925e-06
135 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 14 1142 1.139e-07 3.925e-06
136 POSITIVE REGULATION OF PROTEIN IMPORT 6 104 1.181e-07 4.04e-06
137 B CELL RECEPTOR SIGNALING PATHWAY 5 54 1.336e-07 4.537e-06
138 LIPID METABOLIC PROCESS 14 1158 1.352e-07 4.558e-06
139 CELLULAR RESPONSE TO NITROGEN COMPOUND 10 505 1.391e-07 4.656e-06
140 MULTICELLULAR ORGANISMAL HOMEOSTASIS 8 272 1.472e-07 4.893e-06
141 ENDOCYTOSIS 10 509 1.496e-07 4.938e-06
142 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 10 514 1.638e-07 5.368e-06
143 ENDOTHELIAL CELL MIGRATION 5 57 1.76e-07 5.726e-06
144 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 8 282 1.94e-07 6.226e-06
145 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 13 1004 1.939e-07 6.226e-06
146 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 15 1395 1.957e-07 6.236e-06
147 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 8 289 2.339e-07 7.404e-06
148 RESPONSE TO PEPTIDE 9 404 2.386e-07 7.501e-06
149 RESPONSE TO ABIOTIC STIMULUS 13 1024 2.433e-07 7.597e-06
150 CELL DEVELOPMENT 15 1426 2.602e-07 8.072e-06
151 POSITIVE REGULATION OF CHEMOTAXIS 6 120 2.768e-07 8.528e-06
152 POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS 8 296 2.807e-07 8.592e-06
153 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 6 121 2.907e-07 8.841e-06
154 VESICLE MEDIATED TRANSPORT 14 1239 3.096e-07 9.355e-06
155 CELLULAR RESPONSE TO HORMONE STIMULUS 10 552 3.163e-07 9.494e-06
156 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 16 1672 3.301e-07 9.846e-06
157 INOSITOL LIPID MEDIATED SIGNALING 6 124 3.361e-07 9.96e-06
158 REGULATION OF PROTEIN TARGETING 8 307 3.703e-07 1.09e-05
159 LIPID MODIFICATION 7 210 4.119e-07 1.205e-05
160 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 6 129 4.245e-07 1.235e-05
161 REGULATION OF CELL JUNCTION ASSEMBLY 5 68 4.302e-07 1.236e-05
162 RESPONSE TO HORMONE 12 893 4.292e-07 1.236e-05
163 REGULATION OF CELL PROLIFERATION 15 1496 4.825e-07 1.377e-05
164 RESPONSE TO GROWTH HORMONE 4 30 5.871e-07 1.666e-05
165 CELLULAR GLUCOSE HOMEOSTASIS 5 75 7.04e-07 1.985e-05
166 REGULATION OF PROTEIN LOCALIZATION 12 950 8.281e-07 2.321e-05
167 REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS 5 78 8.568e-07 2.387e-05
168 CELLULAR RESPONSE TO INSULIN STIMULUS 6 146 8.794e-07 2.436e-05
169 RESPONSE TO GROWTH FACTOR 9 475 9.241e-07 2.544e-05
170 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 13 1152 9.302e-07 2.546e-05
171 INSULIN RECEPTOR SIGNALING PATHWAY 5 80 9.724e-07 2.646e-05
172 TISSUE MIGRATION 5 84 1.24e-06 3.356e-05
173 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 12 1008 1.545e-06 4.155e-05
174 POSITIVE REGULATION OF CELL ADHESION 8 376 1.701e-06 4.548e-05
175 POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS 3 11 1.734e-06 4.562e-05
176 WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY 4 39 1.736e-06 4.562e-05
177 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 9 513 1.745e-06 4.562e-05
178 POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 3 11 1.734e-06 4.562e-05
179 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 8 381 1.876e-06 4.877e-05
180 POSITIVE REGULATION OF GLUCOSE TRANSPORT 4 42 2.351e-06 6.077e-05
181 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 8 404 2.899e-06 7.452e-05
182 REGULATION OF GLUCOSE TRANSPORT 5 100 2.945e-06 7.53e-05
183 REGULATION OF CHEMOTAXIS 6 180 2.976e-06 7.566e-05
184 REGULATION OF CELLULAR PROTEIN LOCALIZATION 9 552 3.181e-06 7.958e-05
185 ANATOMICAL STRUCTURE HOMEOSTASIS 7 285 3.165e-06 7.958e-05
186 REGULATION OF CELL MORPHOGENESIS 9 552 3.181e-06 7.958e-05
187 REGULATION OF PROTEIN IMPORT 6 183 3.274e-06 8.146e-05
188 VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY 3 14 3.808e-06 9.424e-05
189 INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 5 106 3.925e-06 9.663e-05
190 REGULATION OF RESPONSE TO EXTERNAL STIMULUS 11 926 4.712e-06 0.0001154
191 SINGLE ORGANISM BIOSYNTHETIC PROCESS 13 1340 4.999e-06 0.0001218
192 REGULATION OF ENDOCYTOSIS 6 199 5.306e-06 0.0001286
193 REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT 3 16 5.84e-06 0.0001408
194 REGULATION OF HOMEOSTATIC PROCESS 8 447 6.103e-06 0.0001464
195 RESPONSE TO INSULIN 6 205 6.292e-06 0.0001494
196 NEURON PROJECTION GUIDANCE 6 205 6.292e-06 0.0001494
197 REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 3 17 7.08e-06 0.0001647
198 NEGATIVE REGULATION OF ANOIKIS 3 17 7.08e-06 0.0001647
199 PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING 3 17 7.08e-06 0.0001647
200 REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS 3 17 7.08e-06 0.0001647
201 SINGLE ORGANISM CELL ADHESION 8 459 7.406e-06 0.0001715
202 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 6 218 8.942e-06 0.000206
203 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 6 220 9.42e-06 0.0002159
204 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 7 337 9.486e-06 0.0002164
205 CELL DEATH 11 1001 9.879e-06 0.0002231
206 POSITIVE REGULATION OF LIPID METABOLIC PROCESS 5 128 9.878e-06 0.0002231
207 REGULATION OF GLUCOSE IMPORT 4 60 9.945e-06 0.0002235
208 POSITIVE REGULATION OF CELL PROLIFERATION 10 814 1.031e-05 0.0002307
209 REGULATION OF CELL ACTIVATION 8 484 1.089e-05 0.0002425
210 REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY 6 232 1.274e-05 0.0002824
211 PEPTIDYL AMINO ACID MODIFICATION 10 841 1.37e-05 0.0003006
212 POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION 3 21 1.376e-05 0.0003006
213 BONE RESORPTION 3 21 1.376e-05 0.0003006
214 CELLULAR RESPONSE TO UV 4 66 1.455e-05 0.0003165
215 NON CANONICAL WNT SIGNALING PATHWAY 5 140 1.526e-05 0.0003287
216 REGULATION OF SYNAPTIC PLASTICITY 5 140 1.526e-05 0.0003287
217 CELL PROLIFERATION 9 672 1.551e-05 0.0003326
218 CELLULAR HOMEOSTASIS 9 676 1.626e-05 0.000347
219 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 7 368 1.676e-05 0.0003562
220 POSITIVE REGULATION OF CYTOKINE PRODUCTION 7 370 1.736e-05 0.0003671
221 PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING 3 23 1.827e-05 0.0003846
222 REGULATION OF POSITIVE CHEMOTAXIS 3 24 2.084e-05 0.0004291
223 POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY 3 24 2.084e-05 0.0004291
224 REGULATION OF CELL CELL ADHESION 7 380 2.061e-05 0.0004291
225 REGULATION OF ANOIKIS 3 24 2.084e-05 0.0004291
226 POSITIVE REGULATION OF LAMELLIPODIUM ORGANIZATION 3 24 2.084e-05 0.0004291
227 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 14 1784 2.254e-05 0.000462
228 CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS 4 74 2.293e-05 0.000468
229 THYROID GLAND DEVELOPMENT 3 25 2.365e-05 0.0004805
230 AMEBOIDAL TYPE CELL MIGRATION 5 154 2.417e-05 0.0004889
231 CELLULAR COMPONENT MORPHOGENESIS 10 900 2.459e-05 0.0004953
232 CELL PROJECTION ORGANIZATION 10 902 2.506e-05 0.0005026
233 NEURON PROJECTION DEVELOPMENT 8 545 2.56e-05 0.0005113
234 GLAND DEVELOPMENT 7 395 2.641e-05 0.0005251
235 CELLULAR RESPONSE TO STRESS 13 1565 2.662e-05 0.0005262
236 PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING 3 26 2.669e-05 0.0005262
237 LYMPHOCYTE COSTIMULATION 4 78 2.824e-05 0.0005545
238 NEURON PROJECTION MORPHOGENESIS 7 402 2.954e-05 0.0005775
239 REGULATION OF CELL PROJECTION ORGANIZATION 8 558 3.029e-05 0.0005897
240 REGULATION OF CYTOKINE PRODUCTION 8 563 3.228e-05 0.0006258
241 REPRODUCTIVE SYSTEM DEVELOPMENT 7 408 3.247e-05 0.0006268
242 REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 6 278 3.531e-05 0.0006761
243 CELLULAR CHEMICAL HOMEOSTASIS 8 570 3.524e-05 0.0006761
244 LEUKOCYTE ACTIVATION 7 414 3.563e-05 0.0006794
245 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 8 573 3.658e-05 0.0006938
246 RESPONSE TO CARBOHYDRATE 5 168 3.668e-05 0.0006938
247 REGULATION OF VACUOLAR TRANSPORT 3 29 3.733e-05 0.0007033
248 GLUCOSE HOMEOSTASIS 5 170 3.882e-05 0.0007254
249 CARBOHYDRATE HOMEOSTASIS 5 170 3.882e-05 0.0007254
250 POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE 5 172 4.105e-05 0.000764
251 CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS 3 30 4.142e-05 0.0007678
252 TISSUE REMODELING 4 87 4.343e-05 0.0008019
253 REGULATION OF CELLULAR COMPONENT BIOGENESIS 9 767 4.386e-05 0.0008067
254 NEUROGENESIS 12 1402 4.404e-05 0.0008067
255 HOMEOSTASIS OF NUMBER OF CELLS 5 175 4.458e-05 0.0008134
256 REGULATION OF ORGANELLE ORGANIZATION 11 1178 4.485e-05 0.0008151
257 NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 4 88 4.542e-05 0.0008192
258 POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 4 88 4.542e-05 0.0008192
259 PHOSPHATIDYLGLYCEROL METABOLIC PROCESS 3 31 4.578e-05 0.0008193
260 HOMEOSTASIS OF NUMBER OF CELLS WITHIN A TISSUE 3 31 4.578e-05 0.0008193
261 LEUKOCYTE DIFFERENTIATION 6 292 4.643e-05 0.0008278
262 POSITIVE REGULATION OF LIPID KINASE ACTIVITY 3 32 5.044e-05 0.0008957
263 ESTABLISHMENT OF PROTEIN LOCALIZATION 12 1423 5.093e-05 0.000901
264 CELLULAR RESPONSE TO LIGHT STIMULUS 4 91 5.181e-05 0.0009105
265 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 8 602 5.185e-05 0.0009105
266 MODULATION OF SYNAPTIC TRANSMISSION 6 301 5.496e-05 0.0009614
267 RESPONSE TO FLUID SHEAR STRESS 3 34 6.066e-05 0.001057
268 REGULATION OF HOMOTYPIC CELL CELL ADHESION 6 307 6.131e-05 0.001064
269 BONE REMODELING 3 35 6.624e-05 0.001146
270 POSITIVE REGULATION OF CELL SUBSTRATE ADHESION 4 99 7.202e-05 0.001241
271 CELL PART MORPHOGENESIS 8 633 7.375e-05 0.001266
272 HEART DEVELOPMENT 7 466 7.518e-05 0.001286
273 POSITIVE REGULATION OF CELL DIFFERENTIATION 9 823 7.562e-05 0.001289
274 REGULATION OF LAMELLIPODIUM ORGANIZATION 3 37 7.839e-05 0.001317
275 RESPIRATORY SYSTEM DEVELOPMENT 5 197 7.819e-05 0.001317
276 BIOLOGICAL ADHESION 10 1032 7.831e-05 0.001317
277 RESPONSE TO MOLECULE OF BACTERIAL ORIGIN 6 321 7.843e-05 0.001317
278 ASTROCYTE DIFFERENTIATION 3 39 9.192e-05 0.001532
279 PEPTIDYL TYROSINE AUTOPHOSPHORYLATION 3 39 9.192e-05 0.001532
280 ACTIVATION OF INNATE IMMUNE RESPONSE 5 204 9.218e-05 0.001532
281 TISSUE DEVELOPMENT 12 1518 9.522e-05 0.001577
282 POSITIVE REGULATION OF CELL MATRIX ADHESION 3 40 9.921e-05 0.001637
283 SYSTEM PROCESS 13 1785 0.0001045 0.001718
284 LYMPHOCYTE ACTIVATION 6 342 0.0001111 0.00182
285 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 5 213 0.0001129 0.001844
286 POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS 3 42 0.0001149 0.00187
287 CHEMICAL HOMEOSTASIS 9 874 0.0001197 0.001934
288 NEURON DIFFERENTIATION 9 874 0.0001197 0.001934
289 POSITIVE REGULATION OF HOMEOSTATIC PROCESS 5 216 0.0001206 0.001941
290 ALCOHOL METABOLIC PROCESS 6 348 0.0001221 0.00196
291 REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING 3 43 0.0001233 0.001972
292 WNT SIGNALING PATHWAY 6 351 0.000128 0.00204
293 NEURON DEVELOPMENT 8 687 0.0001302 0.00206
294 SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 6 352 0.00013 0.00206
295 REGULATION OF CELLULAR RESPONSE TO STRESS 8 691 0.0001355 0.002137
296 MAMMARY GLAND DEVELOPMENT 4 117 0.0001377 0.002165
297 LUNG MORPHOGENESIS 3 45 0.0001414 0.002215
298 EMBRYO DEVELOPMENT 9 894 0.0001421 0.002215
299 REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 4 118 0.0001423 0.002215
300 PEPTIDYL THREONINE MODIFICATION 3 46 0.000151 0.002342
301 CYTOKINE PRODUCTION 4 120 0.0001518 0.002347
302 REGULATION OF APOPTOTIC SIGNALING PATHWAY 6 363 0.0001537 0.002368
303 POSITIVE REGULATION OF DEFENSE RESPONSE 6 364 0.000156 0.002396
304 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 6 365 0.0001584 0.002424
305 THYMUS DEVELOPMENT 3 47 0.000161 0.002457
306 HEAD DEVELOPMENT 8 709 0.0001617 0.002458
307 RESPONSE TO UV 4 126 0.0001832 0.002777
308 MUSCLE CELL DIFFERENTIATION 5 237 0.0001859 0.002809
309 REGULATION OF ERK1 AND ERK2 CASCADE 5 238 0.0001896 0.002855
310 FACE DEVELOPMENT 3 50 0.0001937 0.002908
311 MUSCLE CELL DEVELOPMENT 4 128 0.0001946 0.002912
312 BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE 4 131 0.0002127 0.003172
313 TUBE DEVELOPMENT 7 552 0.0002145 0.003189
314 EPITHELIUM DEVELOPMENT 9 945 0.0002155 0.003193
315 B CELL ACTIVATION 4 132 0.000219 0.003229
316 REGULATION OF NEURON DIFFERENTIATION 7 554 0.0002193 0.003229
317 POSITIVE REGULATION OF INNATE IMMUNE RESPONSE 5 246 0.000221 0.003245
318 LIPID CATABOLIC PROCESS 5 247 0.0002252 0.003296
319 MAMMARY GLAND EPITHELIUM DEVELOPMENT 3 53 0.0002305 0.003362
320 ESTABLISHMENT OF LOCALIZATION IN CELL 12 1676 0.0002431 0.003534
321 GLIAL CELL DIFFERENTIATION 4 136 0.0002455 0.003559
322 CELLULAR RESPONSE TO RADIATION 4 137 0.0002525 0.003637
323 ACTIVATION OF MAPK ACTIVITY 4 137 0.0002525 0.003637
324 PLACENTA DEVELOPMENT 4 138 0.0002596 0.003728
325 POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS 6 406 0.0002812 0.004026
326 POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 3 57 0.0002861 0.004083
327 CELLULAR RESPONSE TO ABIOTIC STIMULUS 5 263 0.0003009 0.004282
328 VASCULOGENESIS 3 59 0.0003168 0.004495
329 REGULATION OF GOLGI ORGANIZATION 2 12 0.0003221 0.004527
330 CEREBRAL CORTEX GABAERGIC INTERNEURON DIFFERENTIATION 2 12 0.0003221 0.004527
331 TRACHEA MORPHOGENESIS 2 12 0.0003221 0.004527
332 POSITIVE REGULATION OF LYASE ACTIVITY 3 61 0.0003497 0.004886
333 POSITIVE REGULATION OF CYCLASE ACTIVITY 3 61 0.0003497 0.004886
334 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 152 0.000375 0.005224
335 LIPOXYGENASE PATHWAY 2 13 0.0003801 0.005263
336 LYMPH VESSEL MORPHOGENESIS 2 13 0.0003801 0.005263
337 CELL CELL ADHESION 7 608 0.0003854 0.005289
338 REGULATION OF MUSCLE ADAPTATION 3 63 0.0003846 0.005289
339 RESPONSE TO OSMOTIC STRESS 3 63 0.0003846 0.005289
340 RESPONSE TO LIGHT STIMULUS 5 280 0.000401 0.005488
341 PHOSPHATIDYLCHOLINE METABOLIC PROCESS 3 64 0.0004029 0.005493
342 REGULATION OF CYCLIC NUCLEOTIDE METABOLIC PROCESS 4 155 0.0004038 0.005493
343 REGULATION OF RESPIRATORY BURST 2 14 0.0004428 0.005989
344 POSITIVE REGULATION OF SPROUTING ANGIOGENESIS 2 14 0.0004428 0.005989
345 APOPTOTIC SIGNALING PATHWAY 5 289 0.0004633 0.006248
346 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 4 162 0.0004771 0.006417
347 PROTEIN LOCALIZATION 12 1805 0.0004814 0.006439
348 POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION 3 68 0.0004816 0.006439
349 VASCULAR PROCESS IN CIRCULATORY SYSTEM 4 163 0.0004883 0.006511
350 CYTOSKELETON ORGANIZATION 8 838 0.0004993 0.006637
351 CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS 2 15 0.0005102 0.006687
352 NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS 2 15 0.0005102 0.006687
353 GABAERGIC NEURON DIFFERENTIATION 2 15 0.0005102 0.006687
354 REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS 2 15 0.0005102 0.006687
355 NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY 2 15 0.0005102 0.006687
356 CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT 3 70 0.0005244 0.006854
357 NEGATIVE REGULATION OF TRANSPORT 6 458 0.0005333 0.006951
358 MORPHOGENESIS OF A BRANCHING STRUCTURE 4 167 0.000535 0.006954
359 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 3 71 0.0005467 0.007085
360 AMMONIUM ION METABOLIC PROCESS 4 169 0.0005596 0.007232
361 NEGATIVE REGULATION OF MOLECULAR FUNCTION 9 1079 0.0005714 0.007364
362 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 5 303 0.0005743 0.007382
363 POSITIVE REGULATION OF LAMELLIPODIUM ASSEMBLY 2 16 0.0005822 0.007422
364 POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 2 16 0.0005822 0.007422
365 PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING 2 16 0.0005822 0.007422
366 STRIATED MUSCLE CELL DIFFERENTIATION 4 173 0.0006109 0.007767
367 GLIOGENESIS 4 175 0.0006379 0.008087
368 IN UTERO EMBRYONIC DEVELOPMENT 5 311 0.0006462 0.008126
369 RESPONSE TO OXYGEN LEVELS 5 311 0.0006462 0.008126
370 POSITIVE REGULATION OF CELL ACTIVATION 5 311 0.0006462 0.008126
371 CENTRAL NERVOUS SYSTEM DEVELOPMENT 8 872 0.0006491 0.008141
372 RESPONSE TO CORTICOSTEROID 4 176 0.0006516 0.008151
373 PHOSPHATIDYLSERINE ACYL CHAIN REMODELING 2 17 0.0006589 0.008176
374 REGULATION OF CHROMATIN BINDING 2 17 0.0006589 0.008176
375 REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 2 17 0.0006589 0.008176
376 RESPONSE TO INORGANIC SUBSTANCE 6 479 0.0006748 0.00835
377 ORGANIC HYDROXY COMPOUND METABOLIC PROCESS 6 482 0.0006971 0.008604
378 RESPONSE TO BIOTIC STIMULUS 8 886 0.0007206 0.00887
379 REGULATION OF MITOCHONDRIAL DEPOLARIZATION 2 18 0.0007402 0.009016
380 REGULATION OF CELL MATURATION 2 18 0.0007402 0.009016
381 OVULATION 2 18 0.0007402 0.009016
382 MAST CELL MEDIATED IMMUNITY 2 18 0.0007402 0.009016
383 POSITIVE REGULATION OF DNA METABOLIC PROCESS 4 185 0.0007852 0.009539
384 POSITIVE REGULATION OF PROTEIN KINASE B SIGNALING 3 81 0.0008033 0.009684
385 PEPTIDYL TYROSINE MODIFICATION 4 186 0.0008012 0.009684
386 POSITIVE REGULATION OF LEUKOCYTE CHEMOTAXIS 3 81 0.0008033 0.009684
387 CELLULAR RESPONSE TO FLUID SHEAR STRESS 2 19 0.0008261 0.009907
388 REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS 2 19 0.0008261 0.009907
389 NEGATIVE REGULATION OF PROTEOLYSIS 5 329 0.0008323 0.009955
NumGOOverlapSizeP ValueAdj. P Value
1 KINASE ACTIVITY 20 842 2.873e-16 2.669e-13
2 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 20 992 6.553e-15 3.044e-12
3 KINASE BINDING 15 606 2.088e-12 6.466e-10
4 RIBONUCLEOTIDE BINDING 22 1860 8.984e-12 2.086e-09
5 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 7 70 1.931e-10 3.145e-08
6 ENZYME BINDING 20 1737 2.031e-10 3.145e-08
7 X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 6 43 5.255e-10 6.974e-08
8 PROTEIN KINASE ACTIVITY 13 640 9.303e-10 1.08e-07
9 PHOSPHATIDYLINOSITOL KINASE ACTIVITY 6 51 1.532e-09 1.581e-07
10 KINASE REGULATOR ACTIVITY 8 186 7.73e-09 7.182e-07
11 PROTEIN SERINE THREONINE KINASE ACTIVITY 10 445 4.274e-08 3.609e-06
12 ADENYL NUCLEOTIDE BINDING 16 1514 8.433e-08 6.528e-06
13 INSULIN RECEPTOR SUBSTRATE BINDING 3 11 1.734e-06 0.0001239
14 CALCIUM DEPENDENT PROTEIN KINASE ACTIVITY 3 12 2.309e-06 0.0001341
15 RECEPTOR SIGNALING PROTEIN ACTIVITY 6 172 2.287e-06 0.0001341
16 PHOSPHOLIPASE ACTIVITY 5 94 2.169e-06 0.0001341
17 PROTEIN KINASE C BINDING 4 50 4.774e-06 0.0002609
18 PROTEIN KINASE C ACTIVITY 3 16 5.84e-06 0.0002855
19 PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY 3 16 5.84e-06 0.0002855
20 LIPASE ACTIVITY 5 117 6.372e-06 0.000296
21 MOLECULAR FUNCTION REGULATOR 12 1353 3.103e-05 0.001373
22 HYDROLASE ACTIVITY ACTING ON ESTER BONDS 9 739 3.282e-05 0.001386
23 PHOSPHOLIPASE A2 ACTIVITY 3 31 4.578e-05 0.001849
24 RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY 4 92 5.407e-05 0.002093
25 PHOSPHORIC ESTER HYDROLASE ACTIVITY 6 368 0.0001656 0.006152
26 ENZYME REGULATOR ACTIVITY 9 959 0.0002405 0.008383
27 PROTEIN TYROSINE KINASE BINDING 3 54 0.0002437 0.008383
NumGOOverlapSizeP ValueAdj. P Value
1 PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX 7 20 1.357e-14 7.924e-12
2 EXTRINSIC COMPONENT OF MEMBRANE 11 252 7.106e-12 2.075e-09
3 CELL LEADING EDGE 9 350 7.067e-08 1.376e-05
4 LAMELLIPODIUM 7 172 1.061e-07 1.549e-05
5 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 7 237 9.288e-07 0.0001085
6 CELL SUBSTRATE JUNCTION 8 398 2.595e-06 0.0002526
7 CELL JUNCTION 12 1151 6.1e-06 0.0005089
8 ANCHORING JUNCTION 8 489 1.174e-05 0.0008568
9 ACTIN FILAMENT 4 70 1.839e-05 0.001194
10 MEMBRANE MICRODOMAIN 6 288 4.3e-05 0.002283
11 PLASMA MEMBRANE RAFT 4 86 4.15e-05 0.002283
12 ACTIN CYTOSKELETON 7 444 5.548e-05 0.0027
13 CATALYTIC COMPLEX 10 1038 8.219e-05 0.003692
14 CELL PROJECTION 13 1786 0.0001051 0.004383
15 PHOSPHATASE COMPLEX 3 48 0.0001715 0.00626
16 MEMBRANE REGION 10 1134 0.0001706 0.00626
17 EXTRINSIC COMPONENT OF PLASMA MEMBRANE 4 136 0.0002455 0.008434
18 CYTOSKELETON 13 1967 0.0002771 0.008992

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04370_VEGF_signaling_pathway 45 76 6.848e-117 1.233e-114
2 hsa04662_B_cell_receptor_signaling_pathway 27 75 2.494e-56 2.244e-54
3 hsa04650_Natural_killer_cell_mediated_cytotoxicity 28 136 1.058e-50 6.349e-49
4 hsa04664_Fc_epsilon_RI_signaling_pathway 25 79 3.528e-50 1.588e-48
5 hsa04660_T_cell_receptor_signaling_pathway 24 108 8.372e-44 3.014e-42
6 hsa04014_Ras_signaling_pathway 26 236 3.616e-39 1.085e-37
7 hsa04012_ErbB_signaling_pathway 21 87 6.527e-39 1.678e-37
8 hsa04666_Fc_gamma_R.mediated_phagocytosis 20 95 1.162e-35 2.614e-34
9 hsa04510_Focal_adhesion 23 200 9.275e-35 1.855e-33
10 hsa04010_MAPK_signaling_pathway 23 268 1.02e-31 1.836e-30
11 hsa04722_Neurotrophin_signaling_pathway 18 127 1.197e-28 1.958e-27
12 hsa04380_Osteoclast_differentiation 18 128 1.391e-28 2.086e-27
13 hsa04062_Chemokine_signaling_pathway 19 189 2.666e-27 3.692e-26
14 hsa04670_Leukocyte_transendothelial_migration 17 117 3.156e-27 4.058e-26
15 hsa04151_PI3K_AKT_signaling_pathway 21 351 1.907e-25 2.289e-24
16 hsa04960_Aldosterone.regulated_sodium_reabsorption 12 42 3.565e-23 4.01e-22
17 hsa04914_Progesterone.mediated_oocyte_maturation 14 87 4.34e-23 4.595e-22
18 hsa04810_Regulation_of_actin_cytoskeleton 17 214 1.406e-22 1.406e-21
19 hsa04360_Axon_guidance 15 130 1.989e-22 1.884e-21
20 hsa04210_Apoptosis 13 89 6.994e-21 6.295e-20
21 hsa04910_Insulin_signaling_pathway 14 138 3.925e-20 3.364e-19
22 hsa04620_Toll.like_receptor_signaling_pathway 13 102 4.563e-20 3.734e-19
23 hsa04150_mTOR_signaling_pathway 11 52 1.124e-19 8.797e-19
24 hsa04070_Phosphatidylinositol_signaling_system 12 78 1.325e-19 9.938e-19
25 hsa04310_Wnt_signaling_pathway 14 151 1.443e-19 1.039e-18
26 hsa04973_Carbohydrate_digestion_and_absorption 10 44 2.663e-18 1.844e-17
27 hsa04912_GnRH_signaling_pathway 12 101 3.511e-18 2.341e-17
28 hsa04720_Long.term_potentiation 11 70 3.915e-18 2.43e-17
29 hsa04730_Long.term_depression 11 70 3.915e-18 2.43e-17
30 hsa04540_Gap_junction 9 90 3.896e-13 2.338e-12
31 hsa04270_Vascular_smooth_muscle_contraction 9 116 4.031e-12 2.341e-11
32 hsa04020_Calcium_signaling_pathway 10 177 5.571e-12 3.134e-11
33 hsa04630_Jak.STAT_signaling_pathway 9 155 5.574e-11 3.04e-10
34 hsa04916_Melanogenesis 8 101 5.894e-11 3.12e-10
35 hsa04530_Tight_junction 8 133 5.42e-10 2.788e-09
36 hsa04972_Pancreatic_secretion 7 101 2.631e-09 1.315e-08
37 hsa00562_Inositol_phosphate_metabolism 5 57 1.76e-07 8.561e-07
38 hsa04520_Adherens_junction 5 73 6.147e-07 2.912e-06
39 hsa04114_Oocyte_meiosis 5 114 5.611e-06 2.59e-05
40 hsa00590_Arachidonic_acid_metabolism 4 59 9.297e-06 4.184e-05
41 hsa00592_alpha.Linolenic_acid_metabolism 3 20 1.181e-05 5.186e-05
42 hsa04320_Dorso.ventral_axis_formation 3 25 2.365e-05 0.0001013
43 hsa00591_Linoleic_acid_metabolism 3 30 4.142e-05 0.0001734
44 hsa00565_Ether_lipid_metabolism 3 36 7.215e-05 0.0002952
45 hsa04975_Fat_digestion_and_absorption 3 46 0.000151 0.000604
46 hsa04971_Gastric_acid_secretion 3 74 0.0006171 0.002415
47 hsa00564_Glycerophospholipid_metabolism 3 80 0.0007748 0.002967
48 hsa04970_Salivary_secretion 3 89 0.001056 0.00396
49 hsa04621_NOD.like_receptor_signaling_pathway 2 59 0.007807 0.02868
50 hsa04920_Adipocytokine_signaling_pathway 2 68 0.01026 0.03695
51 hsa04144_Endocytosis 2 203 0.0764 0.2696

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

RFPL1S

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-17-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p 11 AKT3 Sponge network -0.223 0.70704 -0.749 0.06936 0.466
2 CASC2 hsa-miR-183-5p;hsa-miR-193b-3p;hsa-miR-193b-5p;hsa-miR-218-5p;hsa-miR-22-5p;hsa-miR-224-5p;hsa-miR-2355-3p;hsa-miR-24-2-5p;hsa-miR-369-3p;hsa-miR-452-5p;hsa-miR-654-3p;hsa-miR-944 12 PRKCA Sponge network -0.561 0.05962 -0.525 0.15685 0.436
3

PCA3

 hsa-miR-141-5p;hsa-miR-16-2-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-23a-3p;hsa-miR-24-3p;hsa-miR-27a-3p;hsa-miR-452-3p;hsa-miR-589-3p;hsa-miR-589-5p;hsa-miR-590-5p;hsa-miR-616-5p 12 PRKCB Sponge network -2.778 8.0E-5 -1.403 0.00367 0.387
4

EMX2OS

 hsa-miR-107;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-362-3p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p;hsa-miR-577 12 AKT3 Sponge network -1.088 0.10042 -0.749 0.06936 0.354
5

MEG3

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-577;hsa-miR-616-5p 11 AKT3 Sponge network -1.645 0.00049 -0.749 0.06936 0.312
6

PCA3

 hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-144-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-96-5p 28 PIK3R1 Sponge network -2.778 8.0E-5 -1.094 2.0E-5 0.309
7

AGAP11

 hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-212-3p;hsa-miR-26b-3p;hsa-miR-320b 11 NFAT5 Sponge network -1.728 0.00016 -0.044 0.82158 0.278
8

PCA3

 hsa-miR-183-5p;hsa-miR-193b-3p;hsa-miR-193b-5p;hsa-miR-200c-3p;hsa-miR-22-5p;hsa-miR-224-5p;hsa-miR-2355-3p;hsa-miR-369-3p;hsa-miR-590-3p;hsa-miR-93-3p;hsa-miR-944 11 PRKCA Sponge network -2.778 8.0E-5 -0.525 0.15685 0.278
9

MEG3

 hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-26b-3p;hsa-miR-320b;hsa-miR-330-3p;hsa-miR-33a-3p;hsa-miR-652-3p 12 NFAT5 Sponge network -1.645 0.00049 -0.044 0.82158 0.265

Quest ID: 8de0de05bcebca4591759a906f19ddfe